Buy Imdelltra in India — Price & Availability

What is Imdelltra used for?

Imdelltra (tarlatamab-dlle) is a bispecific T-cell engager that binds DLL3 (delta-like ligand 3), a protein found on small cell lung cancer cells, and CD3 on T cells at the same time, bringing the patient’s own T cells into contact with the cancer cells so the T cells can destroy them.

It is approved for adults with:

• Extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Imdelltra was the first T-cell engager therapy approved for this setting. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended dosage:
Imdelltra is given as an intravenous infusion on a step-up dosing schedule to reduce the risk of cytokine release syndrome (CRS):

• 1 mg on Cycle 1, Day 1, followed by 10 mg on Day 8, Day 15, and every 2 weeks thereafter, until disease progression or unacceptable toxicity.
• Patients are well hydrated before infusion, given concomitant medications around Cycle 1 doses to reduce CRS, and monitored in an appropriate healthcare setting (with monitoring for a period after the first two doses, accompanied by a caregiver).
• Complete blood count, liver enzymes, and bilirubin are checked before doses per the schedule in the prescribing information.
  The treating oncologist always determines the exact dosing and monitoring plan. Imdelltra must be given only as an IV infusion.

Warnings, precautions, and side effects

Boxed warning — cytokine release syndrome (CRS) and neurologic toxicity, including ICANS: serious or life-threatening CRS and neurologic toxicity (including immune effector cell-associated neurotoxicity syndrome, ICANS) can occur. Treatment is started with the step-up dosing schedule to reduce incidence and severity, and is withheld until the reaction resolves or permanently discontinued based on severity.

• Cytopenias: Imdelltra may reduce blood cell counts, including white blood cells and red blood cells. Regular blood tests help monitor treatment, and any unusual fatigue, bruising, or infection should be reported promptly.
• Infections: Serious infections may occur during Imdelltra treatment. Contact your healthcare provider immediately if you develop fever, chills, cough, sore throat, or any signs of infection requiring prompt medical evaluation.
• Hepatotoxicity: Imdelltra may affect liver function. Your doctor will monitor liver enzymes and bilirubin through regular blood tests during treatment to detect and manage potential liver-related side effects early.
• Hypersensitivity: Allergic or infusion-related reactions may occur during or shortly after Imdelltra infusion. Inform your healthcare team immediately if you experience rash, breathing difficulty, dizziness, or swelling.
• Embryo-fetal toxicity: Imdelltra may harm an unborn baby. Women of childbearing potential should use effective contraception during treatment and discuss pregnancy or breastfeeding plans with their healthcare provider.

Common side effects: The most common side effects (> 20%) include cytokine release syndrome, fatigue, fever (pyrexia), altered taste (dysgeusia), decreased appetite, musculoskeletal pain, constipation, anaemia, and nausea. This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Imdelltra through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Cold-chain import & delivery — Imdelltra is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.

Documents required to import Imdelltra:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports
• Government-issued patient ID proof
• An import permit, where applicable

Because Imdelltra is not sold on the open market in India, there is no fixed MRP. The Imdelltra cost in India depends on a few factors at the time of import:

• The number of vials required across the step-up dosing schedule and subsequent every-2-week doses.
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Imdelltra cost, logistics, and delivery timeline once a valid prescription is shared. Request your Imdelltra quote →

Imdelltra is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid prescription, in line with applicable regulations.

Indian Pharma Network sources Imdelltra from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Imdelltra vials require cold-chain handling: stored refrigerated at 2 °C–8 °C in the original carton, protected from light, and not frozen or shaken. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Is Imdelltra available in India?

Imdelltra (tarlatamab-dlle injections) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, Imdelltra is not commercially marketed in India.

However, patients in India can legally access Imdelltra through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Imdelltra in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Imdelltra price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
• Ensuring full transparency throughout the process

Imdelltra can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status
Imdelltra first received US FDA accelerated approval on 16 May 2024 for extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy, and was granted traditional (full) approval on 19 November 2025 based on the confirmatory DeLLphi-304 trial. It is also progressing through approvals in other markets. As of the current publicly available information, Imdelltra is not commercially marketed in India, which is why the Named Patient route is used.